CTAG1A and neoplasm: Indeed, an affinity‐enhanced anti‐NY‐ESO‐1 TCR has demonstrated exceptional anti‐tumor efficacy in multiple clinical trials without evidence of off‐target toxicities.135, 136, 137, 138